NewsPiero Cingari
IDEXX Laboratories
IDXX · NASDAQ
$557.93+$2.13 (+0.38%)TodayMarket closed ·
Prev close $555.80
Latest news
- Press releaseBusiness Wire
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
- Press releasePRNewswire
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
- Press releaseBusiness Wire
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
- Press releaseBusiness Wire
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
- Press releaseBusiness Wire
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- Press releaseBusiness Wire
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
- NewsVandana Singh
Why Is IDEXX Laboratories Stock Gaining Tuesday?
- News
IDEXX Laboratories Q2 2026 Earnings Call Transcript
- News
IDEXX Laboratories Q2 EPS $4.27 Beats $3.96 Estimate, Sales $1.217B Beat $1.201B Estimate
- Press releaseBusiness Wire
IDEXX Laboratories Announces Second Quarter Results
- Press releaseBusiness Wire
IDEXX Releases 2025 Corporate Responsibility Report, Highlighting Progress Against Its Goals
- Press releaseBusiness Wire
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
- Press releaseBusiness Wire
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
- Press releaseBusiness Wire
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
- Press releaseBusiness Wire
The Biology Came First.
- Press releaseBusiness Wire
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
- NewsVandana Singh
Idexx Laboratories Raises Guidance On Higher Clinical Visits, Diagnostic Frequency
- News
Transcript: IDEXX Laboratories Q1 2026 Earnings Conference Call
- News
CORRECTION: IDEXX Laboratories Q1 EPS $3.47 Beats $3.41 Estimate, Sales $1.141B Beat $1.109B Estimate
- News
Earnings Scheduled For May 5, 2026
- Press releaseBusiness Wire
IDEXX Laboratories Announces First Quarter Results
- Press releaseBusiness Wire
IDEXX Laboratories to Release 2026 First Quarter Financial Results
- Press releaseBusiness Wire
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
- Press releaseBusiness Wire
IDEXX Laboratories to Present at Two Institutional Investor Conferences
- Press releaseBusiness Wire
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
- News
Exploring IDEXX Laboratories's Earnings Expectations
- Press releaseBusiness Wire
Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus
- Press releaseBusiness Wire
IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs
- Press releaseBusiness Wire
IDEXX Announces CEO Succession
- Press releaseBusiness Wire
IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results
- NewsNamrata Sen
From Christmas Treats To GPS Collars: How Americans Are Still Spending On Pets And What It Means For Pet Care Stocks In 2026
- News
P/E Ratio Insights for IDEXX Laboratories
- NewsPiero Cingari
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks
- NewsPiero Cingari
Nvidia, Amazon Extend Rally, Bitcoin Sinks To $107,000: What's Moving Markets Monday?
- NewsVandana Singh
Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook
- NewsAvi Kapoor
IDEXX Laboratories Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
- NewsAvi Kapoor
ON Semiconductor, Williams Companies And 3 Stocks To Watch Heading Into Monday
- News
A Look Into IDEXX Laboratories Inc's Price Over Earnings
- NewsAvi Kapoor
Jim Cramer: This Tech Stock Is A Buy, Louisiana-Pacific Has Been A 'Great Stock'
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.